Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.35 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 5/20 | 0.34 |
| ▸ | FDPS | P14324 | 1/20 | 0.34 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30305975 | 1.00 | GBA1 (0.43) | GBA1ESR1ESR2ALDH1A1KDM4E | |
| SCHEMBL14464977 | 1.00 | GBA1 (0.43) | GBA1ESR1ESR2ALDH1A1KDM4E | |
| SCHEMBL5344274 | 0.84 | GBA1 (0.46) | GBA1ESR1ESR2ALDH1A1KDM4E | |
| SCHEMBL23158732 | 0.84 | GBA1 (0.41) | GBA1ESR1ESR2ALDH1A1KDM4E | |
| SCHEMBL4769838 | 0.81 | GBA1 (0.41) | GBA1ESR1ESR2ALDH1A1KDM4E | |
| SCHEMBL27859444 | 0.79 | GBA1 (0.39) | GBA1ESR1ESR2ALDH1A1KDM4E | |
| SCHEMBL20360950 | 0.79 | GBA1 (0.39) | GBA1ESR1ESR2ALDH1A1KDM4E | |
| SCHEMBL1818006 | 0.78 | GBA1 (0.41) | GBA1ESR1ESR2ALDH1A1KDM4E | |
| SCHEMBL24247763 | 0.78 | GBA1 (0.41) | GBA1ESR1ESR2ALDH1A1KDM4E | |
| SCHEMBL30630352 | 0.77 | ESR1 (0.42) | ESR1ESR2NOS2MBOAT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230270751-A1 | BENZODIAZEPINE DERIVATIVES USEFUL IN TREATING A RESPIRATORY SYNCYTIAL VIRUS INFECTION | PFIZER INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230270751-A1 | BENZODIAZEPINE DERIVATIVES USEFUL IN TREATING A RESPIRATORY SYNCYTIAL VIRUS INFECTION | PFIZER INC. | 2023-08-31 | — | — | US | disclosed |
| CN-116075516-A | Benzodiazepine derivatives useful for the treatment of respiratory syncytial virus infection | 辉瑞大药厂 | 2023-05-05 | — | — | CN | disclosed |
| WO-2022008911-A1 | BENZODIAZEPINE DERIVATIVES USEFUL IN TREATING A RESPIRATORY SYNCYTIAL VIRUS INFECTION | ReViral Limited (GB) | 2022-01-13 | — | — | WO | disclosed |
| EP-1562588-A4 | USE OF PDE4 INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS | MERCK & CO INC (US) | 2007-10-31 | — | — | EP | disclosed |
| EP-1592419-A1 | USE OF PHOSPHODIESTERASE-4 INHIBITORS AS ENHANCERS OF COGNITION | Merck Frosst Canada & Co. (CA) | 2005-11-09 | — | — | EP | disclosed |
| EP-1565466-A2 | METHOD OF PREPARING INHIBITORS OF PHOSPHODIESTERASE-4 | Merck & Co., Inc. (US) | 2005-08-24 | — | — | EP | disclosed |
| EP-1562588-A2 | USE OF PDE4 INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS | Merck & Co., Inc. (US) | 2005-08-17 | — | — | EP | disclosed |
| EP-1436290-A1 | ALKYNE-ARYL-NAPHTHYRIDIN-4(1H)-0NE DERIVATIVES AS TYPE IV PHOSPHODIESTERASE INHIBITOR | Merck Frosst Canada & Co. (CA) | 2004-07-14 | — | — | EP | disclosed |
| WO-2004048377-A2 | METHOD OF PREPARING INHIBITORS OF PHOSPHODIESTERASE-4 | MERCK & CO., INC. (US) | 2004-06-10 | — | — | WO | disclosed |
| WO-2004047836-A1 | USE OF PHOSPHODIESTERASE-4 INHIBITORS AS ENHANCERS OF COGNITION | MERCK FROSST CANADA & CO. (CA) | 2004-06-10 | — | — | WO | disclosed |
| WO-2004045508-A2 | USE OF PDE4 INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS | MERCK & CO., INC. (US) | 2004-06-03 | — | — | WO | disclosed |
| EP-1397359-A1 | 1-BIARYL-1,8-NAPTHYRIDIN-4-ONE PHOSPHODIESTERASE-4 INHIBITORS | Merck Frosst Canada & Co. (CA) | 2004-03-17 | — | — | EP | disclosed |
| WO-2003018579-A1 | ALKYNE-ARYL PHOSPHODIESTERASE-4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-03-06 | — | — | WO | disclosed |
| WO-2002094823-A1 | 1-BIARYL-1,8-NAPTHYRIDIN-4-ONE PHOSPHODIESTERASE-4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230270751-A1 | BENZODIAZEPINE DERIVATIVES USEFUL IN TREATING A RESPIRATORY SYNCYTIAL VIRUS INFECTION | CNR1, CNR2, SIGMAR1 | GBA1 2862/4885ESR1 567/4885ESR2 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.